Hypofractionated Stereotactic Radiotherapy for Orbital Metastases: A Case Report and Review of Literature
- *Corresponding Author:
- Blerina Resuli
Department of Radiotherapy
Policlinico Umberto I
Sapienza University of Rome
Viale Regina Elena 256, 00161, Rome Italy
Tel: +39 06 49973411
Fax: +39 06 49973411
E-mail: [email protected]
Received Date: July 10, 2014; Accepted Date: August 21, 2014; Published Date: August 23, 2014
Citation: Resuli B, Lisi R, De Felice F, Musio D, Tombolini V (2014) Hypofractionated Stereotactic Radiotherapy for Orbital Metastases: A Case Report and Review of Literature. J Cytol Histol 5:273. doi:10.4172/2157-7099.1000273
Copyright: © 2014 Resuli B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: To evaluate the efficacy and clinical outcome of hypofractionated stereotactic radiotherapy (HSRT) in non-small-cell lung cancer (NSCLC) cancer patients with orbital metastasis.
Case report: A 61-year-old man was admitted to the hospital referring right ptosis and dry hacking cough. HSRT was performed for the orbital metastasis followed by chemotherapy with cisplatin (60 mg/m2) and pemetrexed (500 mg/m2) on day 1 every 21 days for 4 cycles and maintenance pemetrexed (500 mg/m2) on day 1 every 21 days. Control TC scan revealed a complete response of the orbital mass.
Conclusion: HSRT should be considered a valid therapeutic alternative in the management of selected patient with orbital metastases.